What is the 13F Pro Quality Score for PTCT?

13F Pro ranks PTC THERAPEUTICS, INC. (PTCT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PTCT's current score at https://13fpro.ai/research/PTCT (free sign-up required for the full ranking).

Which hedge funds own the most PTCT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PTCT include BlackRock,, RTW INVESTMENTS,, JANUS HENDERSON GROUP PLC. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PTCT as soon as new 13F filings post.

Where does 13F Pro source PTCT data?

All PTC THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. PTC THERAPEUTICS, INC. files with the SEC under CIK 1070081. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PTCT in?

PTC THERAPEUTICS, INC. (PTCT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PTCT's revenue?

Per PTC THERAPEUTICS, INC.'s latest 10-Q filed with the SEC on 2026-05-07, the biggest revenue drivers are: Net product revenue ($225.6M, +47% YoY); Royalty revenue ($46.8M, +29% YoY); Collaboration and license revenue ($0.1M, -100% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/PTCT.

What are PTCT's largest expenses?

PTC THERAPEUTICS, INC.'s latest 10-Q reports these as the largest expense items: Cost of product, collaboration and license sales (excl. amortization) ($28.0M, +$15.2M YoY); Research and development ($100.9M, -7% YoY); Interest expense, net ($49.0M, +44% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is PTCT research updated on 13F Pro?

PTCT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PTC THERAPEUTICS, INC.(PTCT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1070081 PTCT stock profile & AI dashboard →

13F Pro Quality Score

80.0/100

Rank #48 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

91.9/100

Profitability

94.8/100

Balance Sheet

98.6/100

Earnings Quality

30.0/100

Free Cash Flow

88.9/100

Institutional Flow

48.6/100

Revenue Scale

61.0/100

Dilution Risk

28.0/100

PTCT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PTC THERAPEUTICS, INC. (PTCT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTCT at 80.0/100 on a 32-signal composite quality model, placing it at rank #48 of 2,879 stocks — the top 5% of the AI-ranked universe. PTCT scores in the top quartile across balance sheet strength (98.6), profitability (94.8), revenue growth (91.9). Areas of concern include earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), PTC THERAPEUTICS, INC. reports quarterly revenue of $272.6M, net income of $-2.8M, free cash flow of $-60.2M. Top institutional holders of PTCT by reported 13-F value include BlackRock,, RTW INVESTMENTS,, JANUS HENDERSON GROUP PLC, based on the most recent SEC filings. PTCT trades on the Nasdaq exchange and files with the SEC under CIK 1070081. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PTC THERAPEUTICS, INC. directly from SEC EDGAR. PTC THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 31 and 83 since 2024, currently 80.0 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.

✦

Fun facts about PTC THERAPEUTICS, INC.

Quirks, history, and lore behind PTCT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · focused on rare diseases · listed on Nasdaq · headquartered in New Jersey.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, with a pipeline heavy enough to keep Wall Street interested despite the company spending more on R&D than it earns most years.
3
The History
Founded in the late 1990s, it built its reputation by developing drugs for conditions so uncommon that most physicians go entire careers never seeing a single patient with them.
4
The Secret
Its core science exploits a cellular trick called stop-codon readthrough — essentially convincing the body's machinery to ignore a premature genetic stop signal that causes disease.
5
The Lore
Its lead drug Translarna (ataluren) targets a specific mutation type in Duchenne muscular dystrophy, a devastating muscle-wasting disease primarily affecting young boys.
6
The Giveaway
Its ticker spells out its mission: fighting rare genetic diseases one stop codon at a time, with Translarna and Emflaza as its flagship therapies for Duchenne patients.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PTCT's Business? Latest 10-Q Breakdown

AI-extracted from PTC THERAPEUTICS, INC.'s 10-Q filed 2026-05-07 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net product revenue surged 47% YoY to $225.6M driven by Sephience launch, but collaboration revenue plummeted from $989.8M in Q1 2025 (Novartis upfront) to near-zero.

Biggest Revenue Drivers

Total revenue: $272.6M-77% YoY

Net product revenue$225.6M+47% YoY

Increase primarily from Sephience ($124.6M), newly launched, partially offset by declines in Emflaza ($21.5M) due to generic competition and Translarna ($59.0M) due to EC's adoption of negative opinion.

Royalty revenue$46.8M+29% YoY

Higher Evrysdi sales drove royalties; company received $46.8M vs. $36.4M YoY from Roche SMA program.

Collaboration and license revenue$0.1M-100% YoY

Q1 2025 included $989.8M Novartis upfront payment (transaction closed January 2025); Q1 2026 reflects only $0.1M for ongoing work.

Largest Expense Items

Cost of product, collaboration and license sales (excl. amortization)$28.0M+$15.2M YoY

Increase from Novartis agreement costs, Upstaza/Kebilidi royalties, and new product launches.

Research and development$100.9M-7% YoY

Decrease reflects focus on differentiated programs; reductions in Global DMD, Gene Therapy, Splicing platform, and Sephience development.

Interest expense, net$49.0M+44% YoY

Increase driven by higher non-cash interest on liability for sale of future royalties (Royalty Pharma A&R agreement).

Selling, general and administrative$86.2M+6% YoY

Increase reflects continued commercial investment supporting expanding product portfolio.

Margins: Gross margin on product sales declined significantly due to higher cost of goods and amortization of intangible assets (Sephience and Upstaza/Kebilidi regulatory milestone costs being amortized). Operating income turned to a loss of $45M vs. profit of $970M YoY, primarily due to the massive decline in collaboration revenue (no repeat of Novartis $1B upfront).

Watch Items from the Filing

Translarna revenue at risk: EC adopted negative opinion in March 2025; company withdrew U.S. NDA in February 2026. Revenue fell 31% YoY to $59.0M; further declines expected as individual EU countries assess continued access. Substantial revenue loss risk.
Emflaza orphan exclusivity cliff: Seven-year U.S. orphan exclusivity for ages 5+ expired February 2024, driving generic competition. Remaining exclusivity for ages 2–4 expires June 2026. Revenue declined 55% YoY to $21.5M.
Novartis votoplam milestone triggered in April 2026: $50M development milestone achieved upon Phase 3 trial initiation (subsequent event). Company eligible for up to $1.9B in total milestones plus profit share and royalties.
Three distributors each represent >10% of net product sales in Q1 2026; customer concentration creates pricing and supply chain risk.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$272.6M

Net Income

Q1 2026

$-2.8M

Free Cash Flow

Q1 2026

$-60.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+114.5% YoY

$1.73BFY 2025

FY22 $698.8MFY23 $937.8MFY24 $806.8MFY25 $1.73B

Net Income

+288.0% YoY

$683.0MFY 2025

FY22 $-559.0MFY23 $-626.6MFY24 $-363.3MFY25 $683.0M

Operating Income

+386.5% YoY

$866.9MFY 2025

FY22 $-447.4MFY23 $-439.5MFY24 $-302.6MFY25 $866.9M

EPS (Diluted)

+264.5% YoY

$7.78FY 2025

FY22 $-7.79FY23 $-8.37FY24 $-4.73FY25 $7.78

Total Assets

+70.0% YoY

$2.90BFY 2025

FY22 $1.71BFY23 $1.90BFY24 $1.71BFY25 $2.90B

Total Debt

+0.4% YoY

$286.6MFY 2025

FY22 $571.7MFY23 $284.2MFY24 $285.4MFY25 $286.6M

Op. Cash Flow

+760.4% YoY

$711.2MFY 2025

FY22 $-356.7MFY23 $-158.4MFY24 $-107.7MFY25 $711.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.73B +114.5%	$806.8M -14.0%	$937.8M +34.2%	$698.8M +29.7%	$538.6M +41.4%	$380.8M
Net Income	$683.0M +288.0%	$-363.3M +42.0%	$-626.6M -12.1%	$-559.0M -6.7%	$-523.9M -19.6%	$-438.2M
Operating Income	$866.9M +386.5%	$-302.6M +31.2%	$-439.5M +1.8%	$-447.4M -19.5%	$-374.4M +13.3%	$-431.8M
EPS (Diluted)	$7.78 +264.5%	$-4.73 +43.5%	$-8.37 -7.4%	$-7.79 -4.8%	$-7.43 -11.9%	$-6.64
Total Assets	$2.90B +70.0%	$1.71B -10.1%	$1.90B +11.1%	$1.71B -12.0%	$1.94B -12.2%	$2.21B
Total Debt	$286.6M +0.4%	$285.4M +0.4%	$284.2M -50.3%	$571.7M +32.5%	$431.4M +39.6%	$309.1M
Operating Cash Flow	$711.2M +760.4%	$-107.7M +32.0%	$-158.4M +55.6%	$-356.7M -41.9%	$-251.3M -29.5%	$-194.1M

Get alerted when PTCT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PTC THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PTCT

BlackRock, Inc.
$882.2M12,948,717 sh
RTW INVESTMENTS, LP
$527.8M7,746,415 sh
JANUS HENDERSON GROUP PLC
$490.0M7,193,433 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$327.3M4,804,594 sh
STATE STREET CORP
$296.1M4,346,519 sh
WELLINGTON MANAGEMENT GROUP LLP
$268.6M3,942,610 sh
VANGUARD CAPITAL MANAGEMENT LLC
$250.5M3,676,256 sh
TORONTO DOMINION BANK
$206.2M3,025,963 sh
GEODE CAPITAL MANAGEMENT, LLC
$150.6M2,209,954 sh
ARMISTICE CAPITAL, LLC
$141.3M2,074,449 sh

Fund	Value	Shares
BlackRock, Inc.	$882.2M	12,948,717
RTW INVESTMENTS, LP	$527.8M	7,746,415
JANUS HENDERSON GROUP PLC	$490.0M	7,193,433
VANGUARD PORTFOLIO MANAGEMENT LLC	$327.3M	4,804,594
STATE STREET CORP	$296.1M	4,346,519
WELLINGTON MANAGEMENT GROUP LLP	$268.6M	3,942,610
VANGUARD CAPITAL MANAGEMENT LLC	$250.5M	3,676,256
TORONTO DOMINION BANK	$206.2M	3,025,963
GEODE CAPITAL MANAGEMENT, LLC	$150.6M	2,209,954
ARMISTICE CAPITAL, LLC	$141.3M	2,074,449

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PTCT on your watchlist

Track score changes the day PTC THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PTCT a good stock to buy?

13F Pro's AI-powered analysis of PTC THERAPEUTICS, INC. (PTCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PTCT are available on the PTCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PTCT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PTCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PTC THERAPEUTICS, INC.'s investment landscape.